Saturday , October 19 2019
Breaking News
Home / BUSINESS / MUTUAL FUNDS / Sun Pharma’s arm presents study results that show significant skin clearance with ILUMYA

Sun Pharma’s arm presents study results that show significant skin clearance with ILUMYA

Sun Pharmaceutical Industries’ one of its wholly owned subsidiaries has presented long-term follow-up data from ILUMYA (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials at the 28th European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.

The data showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis, with more than half of participants achieving at least 90% skin clearance (Psoriasis Area Sensitivity Index (PASI) 90) and no new safety concerns recorded.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.